4536 Stock Overview
Engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
Santen Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1,677.50 |
| 52 Week High | JP¥1,697.50 |
| 52 Week Low | JP¥1,165.50 |
| Beta | 0.20 |
| 11 Month Change | 2.22% |
| 3 Month Change | 12.85% |
| 1 Year Change | 38.64% |
| 33 Year Change | 10.87% |
| 5 Year Change | -5.97% |
| Change since IPO | 442.30% |
Recent News & Updates
Unpleasant Surprises Could Be In Store For Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Shares
Jun 25
Santen Pharmaceutical Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
May 11Recent updates
Shareholder Returns
| 4536 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 2.0% | 2.7% | 3.4% |
| 1Y | 38.6% | 14.7% | 24.1% |
Return vs Industry: 4536 exceeded the JP Pharmaceuticals industry which returned 14.7% over the past year.
Return vs Market: 4536 exceeded the JP Market which returned 24.1% over the past year.
Price Volatility
| 4536 volatility | |
|---|---|
| 4536 Average Weekly Movement | 2.9% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4536 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4536's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1890 | 3,744 | Takeshi Ito | www.santen.com |
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in phase 3 of clinical trials; and latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative which is filed for marketing approval for the treatment of glaucoma and ocular hypertension.
Santen Pharmaceutical Co., Ltd. Fundamentals Summary
| 4536 fundamental statistics | |
|---|---|
| Market cap | JP¥597.34b |
| Earnings (TTM) | JP¥26.64b |
| Revenue (TTM) | JP¥301.97b |
22.4x
P/E Ratio2.0x
P/S RatioIs 4536 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4536 income statement (TTM) | |
|---|---|
| Revenue | JP¥301.97b |
| Cost of Revenue | JP¥123.26b |
| Gross Profit | JP¥178.71b |
| Other Expenses | JP¥152.07b |
| Earnings | JP¥26.64b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 06, 2024
| Earnings per share (EPS) | 74.82 |
| Gross Margin | 59.18% |
| Net Profit Margin | 8.82% |
| Debt/Equity Ratio | 8.8% |
How did 4536 perform over the long term?
See historical performance and comparison